Protein‐Based Artificial Nanosystems in Cancer Therapy

Proteins, like actors, play different roles in specific applications. In the past decade, significant achievements have been made in protein‐engineered biomedicine for cancer therapy. Certain proteins such as human serum albumin, working as carriers for drug/photosensitizer delivery, have entered cl...

Full description

Saved in:
Bibliographic Details
Published in:Small (Weinheim an der Bergstrasse, Germany) Germany), 2020-06, Vol.16 (23), p.e1907256-n/a
Main Authors: Zhang, Nan, Mei, Kun, Guan, Ping, Hu, Xiaoling, Zhao, Yanli
Format: Article
Language:English
Subjects:
Biocompatibility
Biodegradability
Biological activity
Cancer therapies
cancer therapy
catalytic proteins
Chemical compounds
Denaturation
Drug carriers
Drug delivery systems
Drugs
nanomedicine
Nanotechnology
Pharmacology
Proteins
protein‐based nanosystems
Serum albumin
Substrates
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proteins, like actors, play different roles in specific applications. In the past decade, significant achievements have been made in protein‐engineered biomedicine for cancer therapy. Certain proteins such as human serum albumin, working as carriers for drug/photosensitizer delivery, have entered clinical use due to their long half‐life, biocompatibility, biodegradability, and inherent nonimmunogenicity. Proteins with catalytic abilities are promising as adjuvant agents for other therapeutic modalities or as anticancer drugs themselves. These catalytic proteins are usually defined as enzymes with high biological activity and substrate specificity. However, clinical applications of these kinds of proteins remain rare due to protease‐induced denaturation and weak cellular permeability. Based on the characteristics of different proteins, tailor‐made protein‐based nanosystems could make up for their individual deficiencies. Therefore, elaborately designed protein‐based nanosystems, where proteins serve as drug carriers, adjuvant agents, or therapeutic drugs to make full use of their intrinsic advantages in cancer therapy, are reviewed. Up‐to‐date progress on research in the field of protein‐based nanomedicine is provided. Recent significant development of elaborately designed protein‐based artificial nanosystems as drug carriers, adjuvant agents and therapeutic species is summarized. The aim is to stimulate this important research area toward more practical applications.
ISSN:1613-6810
1613-6829
DOI:10.1002/smll.201907256